One of the body’s strongest assets is its own capability to fight diseases. That’s what Syntab Therapeutics makes use of: The activation of the first line of immune defense, the innate immune system in order to fight cancer cells.

Syntab Therapeutics’ novel and innovative concept reprogramming the patient’s own immune system to fight specifically against cancer by small, completely chemically derived molecules called Immune System Engagers (ISErs).

The ISEr concept offers highly specific binding for cancer cells and targets the innate immune system for selective and strong destruction of these cells. The high bioavailability of small ISEr molecules leads to optimal tissue penetration. ISErs are flexible in their molecular design for multivalency and multi-specificity and easy to produce. Based on these properties development and approval times are much shorter compared to large molecules.